Veracyte, Inc. VCYT

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

• Zacks Investment Research 1 oct

  Neogen Stock Rallies 83% YTD: What's Driving the Surge?

  Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.

  

• Zacks Investment Research 30 sept

  Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care

  Smith+Nephew (SNN) launched the EVOS PELVIC Plating System to expand its orthopedic trauma portfolio into pelvic and acetabular fracture management. The system features dedicated plates, cannulated screws, and specialized instruments designed to improve surgical efficiency. The global pelvic trauma market is projected to grow from $2.81 billion in 2025 to $4.79 billion by 2034 at a 6.1% CAGR, driven by increased high-energy fractures and wider adoption of surgical fixation protocols.

  

• Zacks Investment Research 30 sept

  10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises

  10x Genomics has begun commercial shipments of Atera, its next-generation spatial biology platform, with booked orders exceeding 40 instruments and demand surpassing initial 2026 expectations. The platform enables whole-transcriptome analysis with single-cell sensitivity and is gaining traction across academic, translational, and biopharma research. The global spatial transcriptomics market is projected to reach $495.2 million by 2026 with a 14.7% CAGR through 2033.

  

• Zacks Investment Research 30 sept

  Should You Continue to Hold IART Stock in Your Portfolio?

  Integra LifeSciences (IART) reported 1.6% organic growth in Specialty Surgery revenues driven by neurosurgery strength and improved supply reliability. Adjusted EPS rose 24.4% with margin expansion, and the company is ramping up Braintree production for a SurgiMend relaunch. However, elevated leverage at 4.1X and foreign exchange headwinds pressured full-year revenue guidance and financial flexibility.

  

• Zacks Investment Research 29 sept

  Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

  McKesson raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00 following strong Q1 results with 20% EPS growth. The company is benefiting from robust growth in oncology services, specialty distribution, and GLP-1 therapies, which generated $15 billion in Q1 revenues. However, headwinds include branded drug price declines, generic conversion pressure, and regulatory uncertainty around 340B reform and IRA Part D changes.